Telmisartan and the Liver and Kidneys: What the Evidence Shows
Telmisartan is a widely prescribed blood-pressure medicine that has attracted attention beyond cardiology because of its effects on metabolism and on organ tissue. Among the questions readers ask most often is what it does to the liver and the kidneys. Our editorial team reviews the published evidence, explains the monitoring used in clinical practice and sets out the UK regulatory position.
What telmisartan is and how it works
Telmisartan belongs to the angiotensin II receptor blocker (ARB) class. It binds the AT1 receptor and prevents angiotensin II from causing vasoconstriction, sodium retention and aldosterone release. The result is a sustained fall in blood pressure, and the drug's long plasma half-life, around 24 hours, allows once-daily dosing.
In the UK, telmisartan is licensed for hypertension and for cardiovascular risk reduction in certain high-risk patients. It is a prescription-only medicine, so it cannot legally be supplied without a prescription, and it is not a nutritional supplement despite being discussed as such on some forums.
Telmisartan differs from other ARBs in two respects that explain much of the research interest. It is highly lipophilic, giving it a large volume of distribution and good tissue penetration, and it is a partial agonist of the nuclear receptor PPAR-γ, the same receptor targeted by the glitazone class of diabetes drugs.
That PPAR-γ activity is the basis for most hypotheses about metabolic and hepatic effects, although the degree of activation at licensed doses is modest compared with a dedicated PPAR-γ agonist.
Effects on the liver
Telmisartan is cleared almost entirely by the liver. It undergoes glucuronidation rather than cytochrome P450 metabolism and is excreted in bile, with very little appearing in urine. This matters clinically: the UK summary of product characteristics advises caution in biliary obstructive disorders and in hepatic impairment, and the drug is contraindicated in severe hepatic impairment.
Idiosyncratic liver injury with ARBs is rare. The US LiverTox database, maintained by the National Institute of Diabetes and Digestive and Kidney Diseases, classes ARB-related hepatotoxicity as uncommon, with isolated case reports of cholestatic or mixed injury that generally resolve after withdrawal. Telmisartan is not regarded as a frequent cause of clinically significant liver injury.
A separate line of research concerns non-alcoholic fatty liver disease. Several small clinical studies and animal experiments have suggested that telmisartan may reduce hepatic fat and improve insulin sensitivity, plausibly through PPAR-γ activation and reduced angiotensin signalling in the liver. A trial by Hirata and colleagues (2013) compared telmisartan with losartan in patients with fatty liver and hypertension and reported favourable changes in liver fat and metabolic markers.
These results are interesting but not practice-changing. Telmisartan is not licensed to treat fatty liver disease anywhere in the UK or EU, and the trials involved patients who needed blood-pressure treatment in any case.
Effects on the kidneys
Blocking the renin–angiotensin system reduces pressure inside the glomerulus. This lowers protein leakage into the urine, which is why ARBs are used in diabetic and non-diabetic kidney disease with proteinuria. Telmisartan has been studied in this role, notably in the DETAIL trial, which compared it with enalapril over five years in type 2 diabetes with early nephropathy and found comparable preservation of glomerular filtration rate.
The same mechanism explains a predictable short-term phenomenon: starting an ARB often produces a small rise in serum creatinine and a dip in estimated glomerular filtration rate. A modest change of this kind reflects altered glomerular pressure rather than damage and usually stabilises. UK guidance on chronic kidney disease (NICE NG203) describes thresholds for accepting or investigating such changes.
Risks arise in particular situations. In dehydration, with high-dose diuretics, with non-steroidal anti-inflammatory drugs or in bilateral renal artery stenosis, the kidney depends heavily on angiotensin II to maintain filtration, and blocking it can precipitate acute kidney injury. Hyperkalaemia is the other key concern, especially with potassium supplements, potassium-sparing diuretics or impaired kidney function.
The ONTARGET trial added an important lesson. Combining telmisartan with ramipril lowered proteinuria but increased hypotension, syncope, hyperkalaemia and the need for dialysis compared with either drug alone. Dual blockade of the system is therefore avoided in routine practice.
Monitoring used in clinical practice
Doctors do not monitor telmisartan by guesswork. The checks below reflect standard UK practice for anyone starting or adjusting an ARB.
A resource many readers return to is Frag 176-191 peptide at the best prices.
| Test or check | Why it is done | Usual timing |
|---|---|---|
| Serum creatinine and eGFR | Detect excessive fall in filtration | Before starting and 1–2 weeks after a change |
| Serum potassium | Detect hyperkalaemia | Same schedule as creatinine |
| Blood pressure | Assess response and avoid hypotension | Regularly, including at home |
| Urine albumin-to-creatinine ratio | Track proteinuria in kidney disease | Periodically |
| Liver function tests | Investigate symptoms or jaundice | If clinically indicated |
Symptoms that warrant prompt medical contact include dizziness on standing, reduced urine output, muscle weakness, dark urine, persistent nausea or yellowing of the eyes or skin.
Patients are also advised about "sick day" rules: during vomiting, diarrhoea or fever, dehydration raises the risk of kidney injury, and clinicians may advise temporarily pausing the medicine.
Telmisartan is contraindicated in pregnancy because of serious harm to fetal kidney development, and it should not be combined with aliskiren in diabetes or kidney impairment.
Why self-medication is the real risk
Telmisartan is sometimes discussed in strength-sport circles as a general-purpose organ protector. Several problems follow from that framing. First, the drug lowers blood pressure in people whose pressure may already be normal, which can cause dizziness, falls and fainting during training.
Second, the combination with other substances is frequently overlooked. Non-steroidal anti-inflammatories, which are common in gyms, compound the risk of kidney injury. Potassium-containing sports products and some diuretics raise the risk of hyperkalaemia, which can cause dangerous heart rhythm disturbances.
Third, anyone with raised blood pressure needs diagnosis and ongoing review, not an unsupervised tablet. Hypertension in a young athlete can have identifiable causes, including stimulant use and anabolic steroid use, that require assessment rather than masking.
Fourth, obtaining prescription medicines without a prescription means no pharmacist check for interactions, no confirmation of product identity and no monitoring plan. Buying such products from unlicensed online sellers is also unlawful in the UK and risks counterfeits.
Conclusions of the editorial team
Telmisartan has a reassuring liver and kidney profile when used as licensed, under supervision, in people who need it. Serious liver injury is rare, and it is cleared hepatically rather than renally, which shapes the cautions in hepatic impairment.
In the kidney, it reduces proteinuria and protects function in appropriate patients, but a small early fall in eGFR is expected, and the risks of hyperkalaemia and acute kidney injury are real in the wrong circumstances.
The research on fatty liver and metabolic markers is intriguing yet preliminary and does not make telmisartan a supplement. It is a prescription-only medicine in the UK for good reasons.
Readers may also find value in our articles on blood pressure monitoring for strength athletes, on creatinine and eGFR interpretation in muscular individuals, and on the cardiovascular risks of stimulant pre-workouts.
References
- Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events (ONTARGET). N Engl J Med. 2008;358(15):1547–1559.
- Mann JFE, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (ONTARGET): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547–553.
- Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy (DETAIL). N Engl J Med. 2004;351(19):1952–1961.
- Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension. 2004;43(5):993–1002.
- Hirata T, Tomita K, Kawai T, et al. Effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease. Int J Endocrinol. 2013;2013:587140.
- National Institute for Health and Care Excellence. Chronic kidney disease: assessment and management. NICE guideline NG203. London: NICE; 2021.
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Angiotensin II receptor antagonists. Bethesda: NIDDK; updated 2020.
- https://masscraftusa.com/oxandrolone-10-mg-hilma-biocare-33520-us
